Edition:
United Kingdom

Teligent Inc (TLGT.OQ)

TLGT.OQ on NASDAQ Stock Exchange Global Select Market

2.88USD
18 May 2018
Change (% chg)

$0.03 (+1.05%)
Prev Close
$2.85
Open
$2.87
Day's High
$2.89
Day's Low
$2.83
Volume
41,072
Avg. Vol
140,040
52-wk High
$9.53
52-wk Low
$2.43

Latest Key Developments (Source: Significant Developments)

Teligent Reports Q1 Loss Per Share $0.09
Tuesday, 8 May 2018 

May 8 (Reuters) - Teligent Inc ::TELIGENT, INC. ANNOUNCES FIRST QUARTER 2018 RESULTS.TELIGENT INC <<>> Q1 REVENUE FELL 26 PCT TO $14.5 MLN.TELIGENT INC <<>>- QTRLY SHR LOSS $0.09.  Full Article

Prosight Management Reports A Passive Stake Of 6.8 Pct In Teligent
Monday, 7 May 2018 

May 7 (Reuters) - Teligent Inc ::PROSIGHT MANAGEMENT LP REPORTS A PASSIVE STAKE OF 6.8 PERCENT IN TELIGENT AS OF APRIL 27 - SEC FILING.  Full Article

Teligent Inc Announces FDA Approval Of Clobetasol Propionate Cream
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Teligent Inc ::TELIGENT, INC. ANNOUNCES FDA APPROVAL OF CLOBETASOL PROPIONATE CREAM USP, 0.05%.TELIGENT INC - RECEIVED APPROVAL OF CO'S ABBREVIATED NEW DRUG APPLICATION FROM U.S. FDA OF CLOBETASOL PROPIONATE CREAM USP, 0.05%.  Full Article

Teligent Appoints Damian Finio As Chief Financial Officer
Friday, 26 Jan 2018 

Jan 26 (Reuters) - Teligent Inc ::TELIGENT, INC. ANNOUNCES THE APPOINTMENT OF DAMIAN FINIO AS CHIEF FINANCIAL OFFICER.TELIGENT INC - FINIO WILL SUCCEED JENNIFFER COLLINS, WHO IS LEAVING CO TO PURSUE PERSONAL AND PROFESSIONAL OPPORTUNITIES.  Full Article

TELIGENT ANNOUNCES FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Teligent Inc ::TELIGENT, INC. ANNOUNCES FIRST FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%.TELIGENT, INC. ANNOUNCES FIRST FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%.TELIGENT INC- ‍EXPECT TO LAUNCH HYDROCORTISONE BUTYRATE LOTION 0.1%​ IN Q1 OF 2018.  Full Article

TELIGENT ANNOUNCES FDA APPROVAL OF ERYTHROMYCIN TOPICAL SOLUTION USP, 2%
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Teligent Inc ::TELIGENT, INC. ANNOUNCES FDA APPROVAL OF ERYTHROMYCIN TOPICAL SOLUTION USP, 2%.TELIGENT INC- ‍EXPECT TO LAUNCH ERYTHROMYCIN TOPICAL SOLUTION USP, 2% BEFORE THE END 2017.  Full Article

Teligent announces FDA approval of betamethasone dipropionate ointment usp (augmented), 0.05%​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Teligent Inc ::Announces FDA approval of betamethasone dipropionate ointment USP (augmented), 0.05%​.Expect to launch betamethasone dipropionate ointment USP (augmented), 0.05% in Q1 of 2018​.  Full Article

Teligent posts Q3 qtrly ‍loss per share $0.12​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Teligent Inc :Teligent Inc announces third quarter 2017 results.Sees FY 2017 revenue $65 million to $67 million.Q3 revenue fell 15 percent to $13.7 million.Teligent Inc qtrly ‍loss per share $0.12​.Q3 earnings per share view $-0.01, revenue view $19.1 million -- Thomson Reuters I/B/E/S.Teligent Inc - ‍now anticipates gross margin of 38% to 40% for year ending december 31, 2017​.Teligent - Q3 ‍results, revised FY outlook due to knock-on effect of ANDA approval delays, increased competition in one of our largest products​.  Full Article

Teligent opens a product development laboratory in Estonia
Tuesday, 11 Oct 2016 

Teligent Inc :Opened a pharmaceutical product development laboratory in Estonia.  Full Article

Teligent says Health Canada approves 3 baclofen injection products
Thursday, 25 Aug 2016 

Teligent Inc : Teligent Inc announces Health Canada approval of three baclofen injection products . Says based on internal estimates, total addressable market for these products are approximately $1.0 million CAD .Says groups are now preparing for launch of these three products in early 2017.  Full Article

BRIEF-Teligent Reports Q1 Loss Per Share $0.09

* TELIGENT INC- QTRLY SHR LOSS $0.09 Source text for Eikon: Further company coverage: